O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes

Journal of Immunology

Volumn 179, Issue 4, 2007, Pages 2380-2388

  Ninkovic, Tanja ^a   Hanisch, Franz Georg ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCAN; MUCIN 1; PROTEASOME; MUC1 PROTEIN, HUMAN; MUCIN; PEPTIDE; POLYSACCHARIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; ENDOSOME; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANTIGEN PRESENTATION; CELL FREE SYSTEM; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYMOLOGY; GLYCOSYLATION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PROTEIN MOTIF; PROTEIN PROCESSING;

AMINO ACID MOTIFS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL-FREE SYSTEM; DENDRITIC CELLS; ENDOSOMES; EPITOPES, T-LYMPHOCYTE; GLYCOSYLATION; HUMANS; IMMUNOTHERAPY; MUCINS; NEOPLASMS; PEPTIDES; POLYSACCHARIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34848868110     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.4.2380     Document Type: Article

References (33)

1. Gendler, S. J., A. P. Spicer, E. N. Lalani, T. Duhig, N. Peat, L. Pemberton, M. Boshell, and J. Taylor-Papadimitriou. 1991. Structure and biology of a carcinoma-associated mucin, MUC1. Am. Rev. Respir. Dis. 144: 42-47.
2. von Mensdorff-Pouilly, S., E. Petrakou, P. Kenemanns, K. van Uffelen, A. A. Verstraeten, F. G. Snijdewint, G. J. van Kamp, D. J. Schol, C. A. Reis, M. R. Price, et al. 2000. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and N-acetylgalactosamine (GalNAc) peptides. Int. J. Cancer 86: 702-712.
3. Hanisch, F.-G., and S. Müller. 2000. MUC1: the polymorphic appearance of a human mucin. Glycobiology 10: 439-449.
4. Engelmann, K., S. E. Baldus, and F.-G. Hanisch. 2001. Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1. J. Biol. Chem. 276: 27764-27769.
5. Jerome, K. R., D. L. Barnd, K. M. Bendt, C. M. Boyer, J. Taylor-Papadimitriou, I. F. McKenzie, R. C. Bast, and O. J. Finn. 1991. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51: 2908-2916.
6. Domenech, N., R. A. Henderson, and O. J. Finn. 1995. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol. 155: 4766-4774.
7. Brossart, P., K. S. Heinrich, G. Stuhler, L. Behnke, V. L. Reichardt, S. Stevanovic, A. Muhm, H.-G. Rammensee, L. Kanz, and W. Brugger. 1999. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93: 4309-4317.
8. Heukamp, L. C., S. H. van der Burg, J. W. Drijfhout, C. J. Melief, J. Taylor-Papadimitriou, and R. Offringa. 2001. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. In. J. Cancer 91: 385-392.
9. Pisarev, V. M., L. Kinarsky, T. Caffrey, F.-G. Hanisch, S. Sanderson, M. A. Hollingsworth, and S. Sherman. 2005. T-cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1. Int. Immunopharmacol. 5: 315-330.
10. Hiltbold, E. M., M. D. Alter, P. Ciborowski, and O. J. Finn. 1999. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell. Immunol. 194: 143-149.
11. Hiltbold, E. M., A. Vlad, P. Ciborowski, S. C. Watkins, and O. J. Finn. 2000. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J. Immunol. 165: 3730-3741.
12. Vlad, A., S. Müller, M. Cudic, H. Paulsen, L. Otvos, F.-G. Hanisch, and O. J. Finn. 2002. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J. Exp. Med. 196: 1435-1446.
13. Hanisch, F.-G., T. Schwientek, M. S. von Bergwelt-Baildon, J. L. Schultze, and O. J. Finn. 2003. O-linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur. J. Immunol. 33: 3242-3254.
14. Apostolopoulos, V., E. Yuriev, P. A. Ramsland, J. Halton, C. Osinski, W. Li, M. Plebanski, H. Paulsen, and I. F. C. McKenzie. 2003. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc. Natl. Acad. Sci. USA 100: 15029-15034.
15. Stepensky, D., E. Tzehoval, E. Vadai, and L. Eisenbach. 2006. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin. Exp. Immunol. 143: 139-149.
16. Hearn, A. R., L. de Haan, A. J. Pemberton, T. R. Hirst, and A. J. Rivett. 2004. Trafficking of exogenous peptides into proteasome-dependent major histocompatibility complex class I pathway following enterotoxin B subunit-mediated delivery. J. Biol. Chem. 279: 51315-51322.
17. Seifert, U., C. Maranon, A. Shmueli, J. F. Desoutter, L. Wesoloski, K. Janek, P. Henklein, S. Diescher, M. Andrieu, H. de la Salle, et al. 2003. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat. Immunol. 4: 375-379.
18. Chen, L., and M. Jondal. 2004. Endolysosomal processing of exogenous antigen into major histocompatibility complex class I-binding peptides. Scand. J. Immunol. 59: 545-552.
19. Shen, L., L. J. Sigal, M. Boes, and K. L. Rock. 2004. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 21: 155-165.
20. Goldberg, A. L., S. J. Elledge, and J. W. Harper. 2001. The cellular chamber of doom. Sci. Am. 284: 68-73.
21. Tanaka, K., and M. Kasahara. 1998. The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-γ-inducible proteasome activator PA28. Immunol. Rev. 163: 161-176.
22. Boes, B., H. Hengel, T. Ruppert, G. Multhaup, U. H. Koszinowski, and P. M. Kloetzel. 1994. Interferon γ stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J. Exp. Med. 179: 901-909.
23. Suzuki, T. 2005. A simple, sensitive in vitro assay for cytoplasmic deglycosylation by peptide: N-glycanase. Methods 35: 360-365.
24. Skipper, J. C., R. C. Hendrickson, P. H. Gulden, V. Brichard, A. Van Pel, Y. Chen, J. Shabanowitz, T. Wolfel, C. L. Slingluff, T. Boon, et al. 1996. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183: 527-534.
25. Haurum, J. S., G. Arsequell, A. C. Lellouch, S. Y. Wong, R. A. Dwek, A. J. McMichael, and T. Elliott. 1994. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J. Exp. Med. 180: 739-744.
26. Kastrup, I. B., S. Stevanovic, G. Arsequell, G. Valencia, J. Zeuthen, H.-G. Rammensee, T. Elliott, and J. S. Haurum. 2000. Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo. Tissue Antigens 56: 129-135.
27. Haurum, J. S., I. B. Høier, G. Arsequell, A. Neisig, G. Valencia, J. Zeuthen, J. Neefjes, and T. Elliott. 1999. Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J. Exp. Med. 190: 145-150.
28. Tenzer, S., L. Stotze, B. Schönfisch, J. Dengjel, M. Müller, S. Stefanovic, H.-G. Rammensee, and H. Schild. 2004. Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility. J. Immunol. 172: 1083-1091.
29. Hanisch, F. G., S. Müller, H. Hassan, H. Clausen, N. Zachara, A. A. Gooley, H. Paulsen, K. Alving, and J. Peter-Katalinic. 1999. Dynamic epigenetic regulation of initial O-glyco-sylation by UDP-N-acetylgalactosamine: peptide N-acetylgalactosaminyltransferases: site-specific glycosylation of MUC1 repeat peptide influences the substrate qualities at adjacent or distant Ser/Thr positions. J. Biol. Chem. 274: 9946-9954.
30. Hanisch, F. G., C. A. Reis, H. Clausen, and H. Paulsen. 2001. Evidence for glycosylation-dependent activities of polypeptide N-acetylgalactosaminyltransferases rGalNAc-T2 and -T4 on mucin glycopeptides. Glycobiology 11: 731-740.
31. Müller, S., S. Goletz, N. Packer, A. A. Gooley, A. M. Lawson, and F.-G. Hanisch. 1997. Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1. J. Biol. Chem. 272: 24780-24793.
32. Müller, S., K. Alving, J. Peter-Katalinic, N. Zachara, A. A. Gooley, and F.-G. Hanisch. 1999. High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47-D breast cancer cells. J. Biol. Chem. 274: 18165-18172.
33. von Mensdorff-Pouilly, S., L. Kinarsky, K. Engelmann, S. E. Baldus, R. H. Verheijen, M. A. Hollingsworth, V. Pisarev, S. Sherman, and F.-G. Hanisch. 2005. Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. Glycobiology 15: 735-746.